Ascendis Pharma (ASND)
(Real Time Quote from BATS)
$129.29 USD
-7.24 (-5.30%)
Updated Aug 2, 2024 10:50 AM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 9/3/24 |
---|---|
Current Quarter | -1.51 |
EPS Last Quarter | -2.48 |
Last EPS Surprise | -57.96% |
ABR | 1.33 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -5.53 |
Next Year | -1.70 |
EPS (TTM) | -9.61 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 95.80M | 116.42M | 461.19M | 729.87M |
# of Estimates | 6 | 6 | 6 | 6 |
High Estimate | 105.58M | 130.90M | 520.81M | 908.28M |
Low Estimate | 89.13M | 104.89M | 419.89M | 624.12M |
Year ago Sales | 51.59M | 52.02M | 288.27M | 461.19M |
Year over Year Growth Est. | 85.70% | 123.80% | 59.99% | 58.26% |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -1.51 | -1.29 | -5.53 | -1.70 |
# of Estimates | 8 | 6 | 9 | 8 |
Most Recent Consensus | -1.95 | -1.69 | -4.00 | 0.00 |
High Estimate | -0.98 | -0.70 | -3.87 | 2.08 |
Low Estimate | -2.13 | -1.79 | -7.28 | -4.37 |
Year ago EPS | -2.35 | -3.12 | -9.24 | -5.53 |
Year over Year Growth Est. | 35.74% | 58.65% | 40.15% | 69.15% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 1 | 0 |
Up Last 60 Days | 0 | 0 | 1 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 2 | 2 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -1.51 | -1.29 | -5.53 | -1.70 |
7 Days Ago | -1.51 | -1.29 | -5.53 | -1.70 |
30 Days Ago | -1.51 | -1.29 | -5.57 | -1.70 |
60 Days Ago | -1.52 | -1.29 | -5.40 | -1.41 |
90 Days Ago | -1.41 | -1.07 | -5.31 | -1.35 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -1.51 | -1.29 | -4.00 | -1.70 |
Zacks Consensus Estimate | -1.51 | -1.29 | -5.53 | -1.70 |
Earnings ESP | 0.00% | 0.00% | 27.64% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -2.48 | -1.66 | -3.12 | -2.35 | NA |
Estimate | -1.57 | -2.15 | -2.63 | -2.68 | NA |
Difference | -0.91 | 0.49 | -0.49 | 0.33 | -0.15 |
Surprise | -57.96% | 22.79% | -18.63% | 12.31% | -10.37% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more